Friday's Health Winners & Losers
Updated from 2:21 p.m. EDT
Medical-device makers were among the best health care performers of Friday's session.
Avanir Pharmaceuticals (AVNR) continued its recent march higher. Avanir has soared about 265% this week. On Wednesday, the company said it saw positive results from a late-stage clinical trial for diabetic neuropathic pain drug Zenvia. Avanir closed up 50 cents, or 12.8%, to $4.40.Monogram Biosciences (MGRM) was also riding momentum. Thomas Weisel Partners, which began coverage of the stock recently with a rating of market weight, said Monogram's revenue will continue to climb into 2008. The stock, which is up 23% for the week, closed up 23 cents, or 11.1%, to $2.31. The Nasdaq Biotechnology Index, of which both Avanir and Monogram are components, was higher by only 0.6%. The Amex Pharmaceutical Index was up 0.5%, despite a number of components losing ground. Shares of Merck (MRK) were 2.7% higher after Prudential upped its stock price target for the drugmaker to $55 from $48. But rival Schering-Plough (SGP) slid after both AG Edwards and HSBC Securities downgraded the stock. Schering-Plough was down 29 cents, or 0.9%, to $30.71. Also among losers, Pfizer (PFE) said its most-recent quarter was better than expected, but the drugmaker took down its full-year forecast for profits, the low end of which would be more than 10 cents short of what Wall Street wanted to see. Pfizer was off 0.4% to $26.97. Other pharmaceutical companies were mixed. AstraZeneca (AZN) was up 1.1%, Bristol-Myers Squibb (BMY) was up 0.9%, and Eli Lilly (LLY) gained 0.9%. Elsewhere, Amgen (AMGN) was down 0.6%, Teva Pharmaceutical (TEVA) was down 0.9%, and Wyeth (WYE) was up 0.3%.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV